{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:07:57Z","timestamp":1793196477492,"version":"4.5.0"},"reference-count":155,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["ChemThem Grant to Herman S. Overkleeft and Johannes M.F.G Aerts"],"award-info":[{"award-number":["ChemThem Grant to Herman S. Overkleeft and Johannes M.F.G Aerts"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Fabry disease (FD) is a lysosomal storage disorder (LSD) characterized by the deficiency of \u03b1-galactosidase A (\u03b1-GalA) and the consequent accumulation of toxic metabolites such as globotriaosylceramide (Gb3) and globotriaosylsphingosine (lysoGb3). Early diagnosis and appropriate timely treatment of FD patients are crucial to prevent tissue damage and organ failure which no treatment can reverse. LSDs might profit from four main therapeutic strategies, but hitherto there is no cure. Among the therapeutic possibilities are intravenous administered enzyme replacement therapy (ERT), oral pharmacological chaperone therapy (PCT) or enzyme stabilizers, substrate reduction therapy (SRT) and the more recent gene\/RNA therapy. Unfortunately, FD patients can only benefit from ERT and, since 2016, PCT, both always combined with supportive adjunctive and preventive therapies to clinically manage FD-related chronic renal, cardiac and neurological complications. Gene therapy for FD is currently studied and further strategies such as substrate reduction therapy (SRT) and novel PCTs are under investigation. In this review, we discuss the molecular basis of FD, the pathophysiology and diagnostic procedures, together with the current treatments and potential therapeutic avenues that FD patients could benefit from in the future.<\/jats:p>","DOI":"10.3390\/biom11020271","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T18:45:00Z","timestamp":1613155500000},"page":"271","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4269-7323","authenticated-orcid":false,"given":"Ken","family":"Kok","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-7278","authenticated-orcid":false,"given":"Kimberley C.","family":"Zwiers","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7031-3390","authenticated-orcid":false,"given":"Rolf G.","family":"Boot","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermen S.","family":"Overkleeft","sequence":"additional","affiliation":[{"name":"Department of Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8168-2565","authenticated-orcid":false,"given":"Johannes M. F. G.","family":"Aerts","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-3902","authenticated-orcid":false,"given":"Marta","family":"Artola","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","article-title":"A Case of Angeo-Keratoma","volume":"10","author":"Anderson","year":"1898","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01986897","article-title":"Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)","volume":"43","author":"Fabry","year":"1898","journal-title":"Arch. Dermatol. Res."},{"key":"ref_3","unstructured":"Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D. (2001). \u03b1-Galactosidase a Deficiency. Fabry Disease. The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill. [8th ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/S0021-9258(18)51888-3","article-title":"Fabry\u2019s Disease: Classification as a sphingolipidosis and partial char-acterization of a novel glycolipid","volume":"238","author":"Sweeley","year":"1963","journal-title":"J. Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic Defect in Fabry\u2019s Disease","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry\u2019s Disease: Alpha-Galactosidase Deficiency","volume":"167","author":"Kint","year":"1970","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF00446279","article-title":"Characterization of \u03b1-galactosidase isoen-zymes in normal and fabry human-Chinese hamster somatic cell hybrids","volume":"36","author":"Hamers","year":"1977","journal-title":"Hum. Genet."},{"key":"ref_8","first-page":"305","article-title":"Localization of a gene for human \u03b1-galactosidase B (=N-Acetyl-\u03b1-D-Galactosaminidase) on chromosome 22","volume":"44","author":"Westerveld","year":"1978","journal-title":"Qual. Life Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10038-003-0098-z","article-title":"Structural and immunocytochemical studies on \u03b1-N-acetylgalactosaminidase deficiency (Schindler\/Kanzaki disease)","volume":"49","author":"Sakuraba","year":"2003","journal-title":"J. Hum. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3389\/fpls.2017.01026","article-title":"Human Alpha Galactosidases Transiently Produced in Nicotiana benthamiana Leaves: New Insights in Substrate Specificities with Relevance for Fabry Disease","volume":"8","author":"Kytidou","year":"2017","journal-title":"Front. Plant. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1016\/S0021-9258(19)86664-4","article-title":"Studies on human liver \u03b1-galactosidases. II. Purification and enzymatic properties of \u03b1-galactosidase B (\u03b1-N-acetylgalactosaminidase)","volume":"254","author":"Dean","year":"1979","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The Molecular Defect Leading to Fabry Disease: Structure of Human \u03b1-Galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J. Mol. Biol."},{"key":"ref_13","first-page":"73","article-title":"Fabry disease in a Japanese population-molecular and biochemical characteris-tics","volume":"17","author":"Sakuraba","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cge.12449","article-title":"Diagnostic dilemmas in Fabry disease: A case series study on GLA mutations of unknown clinical significance","volume":"88","author":"Smid","year":"2015","journal-title":"Clin. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/gim.2016.55","article-title":"Is it Fabry disease?","volume":"18","author":"Schiffmann","year":"2016","journal-title":"Genet. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1012447102358","article-title":"Natural history of Fabry disease in affected males and obligate carrier females","volume":"24","author":"MacDermot","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.gene.2012.06.013","article-title":"X-inactivation in Fabry disease","volume":"505","author":"Elstein","year":"2012","journal-title":"Gene"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"D\u2019Avanzo, F., Rigon, L., Zanetti, A., and Tomanin, R. (2020). Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041258"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/0006-291X(72)90310-5","article-title":"A hypothesis for I-cell disease: Defective hydrolases that do not enter lysosomes","volume":"49","author":"Hickman","year":"1972","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_22","first-page":"1","article-title":"A systematic review on screening for Fabry disease: Prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"Smid","year":"2013","journal-title":"J. Med. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screen-ing in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: New markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2014","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cjca.2017.04.015","article-title":"Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy","volume":"33","author":"Yogasundaram","year":"2017","journal-title":"Can. J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from mul-tiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","article-title":"Manifestations of Fabry disease in placental tissue","volume":"29","author":"Vedder","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"\u03b1-Galactosidase A deficient mice: A model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","first-page":"418","article-title":"\u03b1-Galactosidase A-deficient rats accumulate glycosphingolipids and develop car-diorenal phenotypes of Fabry disease","volume":"33","author":"Miller","year":"2019","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_31","first-page":"71","article-title":"The Biology of the Gaucher Cell: The Cradle of Human Chitinases","volume":"252","author":"Bussink","year":"2006","journal-title":"Virus Entry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ymgme.2006.04.013","article-title":"Plasma chitotriosidase in male Fabry patients: A marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy","volume":"89","author":"Vedder","year":"2006","journal-title":"Mol. Genet. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ymgme.2014.11.005","article-title":"Absence of \u03b1-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts","volume":"114","author":"Fuller","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: Formation of gly-cosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ymgme.2015.12.006","article-title":"Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders","volume":"117","author":"Ferraz","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_38","first-page":"128","article-title":"Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry","volume":"883\u2013884","author":"Tholey","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb\u2083-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2017.08.004","article-title":"A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease","volume":"122","author":"Talbot","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"129437","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding and treatment of Fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","article-title":"Fabry disease: Reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts","volume":"82","author":"Schmidt","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Stepien, K.M., Roncaroli, F., Turton, N., Hendriksz, C.J., Roberts, M., Heaton, R.A., and Hargreaves, I.P. (2020). Mechanisms of Mitochondrial Dysfunction in Lysosomal Storage Disorders: A Review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082596"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ivanova, M. (2020). Altered Sphingolipids Metabolism Damaged Mitochondrial Functions: Lessons Learned From Gaucher and Fabry Diseases. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041116"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant \u03b1-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: Biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: A key feature of Fabry disease with potential therapeutic implica-tions","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.2013.520","article-title":"Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease","volume":"86","author":"Shu","year":"2014","journal-title":"Kidney Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/EBC20190090","article-title":"Lyso-glycosphingolipids: Presence and consequences","volume":"64","author":"Ferraz","year":"2020","journal-title":"Essays Biochem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","article-title":"The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain","volume":"594","author":"Choi","year":"2015","journal-title":"Neurosci. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","article-title":"Small fiber neuropathy in Fabry disease","volume":"106","author":"Biegstraaten","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_54","first-page":"1797","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: Im-plications for Fabry nephropathy","volume":"26","year":"2011","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Carpio","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2018.10.007","article-title":"Dissociation of globotriaosylceramide and impaired endothelial function in \u03b1-galactosidase-A deficient EA.hy926 cells","volume":"125","author":"Kaissarian","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"MVasculopathy in patients with Fabry disease: Current controversies and re-search directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4161\/auto.25560","article-title":"The variability of au-tophagy and cell death susceptibility: Unanswered questions","volume":"9","author":"Loos","year":"2013","journal-title":"Autophagy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2051-5960-2-20","article-title":"Autophagy-lysosome pathway associated neuropathology and axonal degenera-tion in the brains of alpha-galactosidase A-deficient mice","volume":"2","author":"Nelson","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4161\/auto.6.5.11943","article-title":"Autophagosome maturation is impaired in Fabry disease","volume":"6","author":"Brakch","year":"2010","journal-title":"Autophagy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF00296520","article-title":"A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier","volume":"90","author":"Uchino","year":"1995","journal-title":"Acta Neuropathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10545-011-9308-6","article-title":"Biomarkers in the diagnosis of lysosomal storage disorders: Proteins, lipids, and inhibodies","volume":"34","author":"Aerts","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of Globotriaosylsphingosine in Plasma and Urine of Fabry Patients by Stable Isotope Ultraperformance Liquid Chromatography\u2013Tandem Mass Spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cca.2017.01.014","article-title":"Simultaneous quantitation of sphingoid bases by UPLC-ESI-MS\/MS with identi-cal 13 C-encoded internal standards","volume":"466","author":"Mirzaian","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"ref_65","first-page":"17.23.1","article-title":"Tandem Mass Spectrometry Quantitation of Lyso-Gb 3 and Six Related Analogs in Plasma for Fabry Disease Patients","volume":"90","author":"Boutin","year":"2016","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1515\/cclm-2018-1301","article-title":"Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphin-golipidoses: A comparative study","volume":"57","author":"Polo","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ejhg.2011.87","article-title":"Fabry or not Fabry-a question of ascertainment","volume":"19","author":"Houge","year":"2011","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2215\/CJN.09480819","article-title":"The Changing Landscape of Fabry Disease","volume":"15","author":"Svarstad","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41436-020-01041-5","article-title":"Correction: Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"D490","DOI":"10.1093\/nar\/gkt1178","article-title":"The carbohydrate-active enzymes database (CAZy) in 2013","volume":"42","author":"Lombard","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"21560","DOI":"10.1074\/jbc.M110.118588","article-title":"Interconversion of the spec-ificities of human lysosomal enzymes associated with Fabry and Schindler diseases","volume":"285","author":"Tomasic","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"16965","DOI":"10.1021\/jacs.0c05592","article-title":"Glycoside hydrolases restrict the side chain conformation of their sub-strates to gain additional transition state stabilization","volume":"142","author":"Crich","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1074\/jbc.M109.060145","article-title":"Catalytic Mechanism of Human \u03b1-Galactosidase","volume":"285","author":"Guce","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1469-185X.1953.tb01386.x","article-title":"Stereochemistry and the mechanism of enzymatic reactions","volume":"28","author":"Koshland","year":"1953","journal-title":"Biol. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sbi.2014.06.003","article-title":"Dissecting conformational contribu-tions to glycosidase catalysis and inhibition","volume":"28","author":"Speciale","year":"2014","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0021-9258(18)68421-2","article-title":"2-Deoxy-2-fluoro-D-glycosyl fluorides. A new class of specific mechanism-based glycosidase inhibitors","volume":"263","author":"Withers","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0014-5793(81)80962-3","article-title":"Active site-directed inhibition of galactosidases by conduritol C epoxides (1,2-anhydro-EPI-NEO-inositol)","volume":"135","author":"November","year":"1981","journal-title":"Febs Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1002\/ejoc.201402589","article-title":"Synthesis of \u03b1- and \u03b2-Galactopyranose-Configured Isomers of Cyclophellitol and Cyclophellitol Aziridine","volume":"2014","author":"Willems","year":"2014","journal-title":"Eur. J. Org. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9233","DOI":"10.1039\/C9SC03342D","article-title":"\u03b1-d-Gal-cyclophellitol cyclosulfamidate is a Michaelis complex analog that stabi-lizes therapeutic lysosomal \u03b1-galactosidase A in Fabry disease","volume":"10","author":"Artola","year":"2019","journal-title":"Chem. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cbpa.2019.05.030","article-title":"An overview of activity-based probes for glycosidases","volume":"53","author":"Wu","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0008-6215(00)90138-1","article-title":"Synthesis of 5-amino-5-deoxy-d-galactopyranose and 1,5-dideoxy-1,5-imino-d-galactitol, and their inhibition of \u03b1- and \u03b2-d-galactosidases","volume":"155","author":"Legler","year":"1986","journal-title":"Carbohydr. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1021\/ja507040n","article-title":"Potent and Selective Activity-Based Probes for GH27 Human Retaining \u03b1-Galactosidases","volume":"136","author":"Willems","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10042","DOI":"10.1074\/jbc.RA118.001774","article-title":"Nicotiana benthamiana\u03b1-galactosidase A1.1 can functionally complement human \u03b1-galactosidase A deficiency associated with Fabry disease","volume":"293","author":"Kytidou","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0140-6736(95)92597-X","article-title":"Allogeneic bone marrow transplantation for lysosomal storage diseases","volume":"345","author":"Hoogerbrugge","year":"1995","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1038\/bmt.2008.62","article-title":"The controversial and changing role of haematopoietic cell transplantation for lyso-somal storage disorders: An update","volume":"41","author":"Rovelli","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1098\/rstb.2003.1269","article-title":"Enzyme replacement therapy: Conception, chaos and culmination","volume":"358","author":"Brady","year":"2003","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2016.10.030","article-title":"Roscoe O. Brady: Physician whose pioneering discoveries in lipid bio-chemistry revolutionized treatment and understanding of lysosomal diseases","volume":"68","author":"Aerts","year":"2018","journal-title":"Blood Cells. Mol. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and Efficacy of Recombinant Human \u03b1-Galactosidase A Replacement Therapy in Fabry\u2019s Disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in fabry disease a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"ref_90","unstructured":"European Medicines Agency Replagal (2021, February 08). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/replagal-epar-product-information_en.pdf."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/345309","article-title":"Recombinant Enzyme Therapy for Fabry Disease: Absence of Editing of Human \u03b1-Galactosidase A mRNA","volume":"72","author":"Blom","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured hu-man Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J. Hum. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Ivanova, M.M. (2020). Rapid Clathrin-Mediated Uptake of Recombinant \u03b1-Gal-A to Lysosome Acti-vates Autophagy. Biomolecules, 10.","DOI":"10.3390\/biom10060837"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Prabakaran, T., Nielsen, R., Larsen, J.V., S\u00f8rensen, S.S., Rasmussen, U.F.-, Saleem, M.A., Petersen, C.M., Verroust, P.J., and Christensen, E.I. (2011). Receptor-Mediated Endocytosis of \u03b1-Galactosidase A in Human Podocytes in Fabry Disease. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025065"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/anie.201600817","article-title":"Chemoenzymatic Synthesis of a Phosphorylated Glycoprotein","volume":"55","author":"Priyanka","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09809-3","article-title":"The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells","volume":"10","author":"Tian","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/acs.bioconjchem.8b00133","article-title":"Development and Analytical Characterization of Pegunigalsidase Alfa, a Chemi-cally Cross-Linked Plant Recombinant Human \u03b1-Galactosidase-A for Treatment of Fabry Disease","volume":"29","author":"Ruderfer","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fab-ry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jimd.12228","article-title":"Developments in the treatment of Fabry disease","volume":"43","author":"Hollak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"En-zyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: A biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Rombach, S.M., Aerts, J.M.F.G., Poorthuis, B.J.H.M., Groener, J.E.M., Donker-Koopman, W., Hendriks, E., Mirzaian, M., Kuiper, S., Wijburg, F.A., and Hollak, C.E.M. (2012). Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047805"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the po-tential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Goyal","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1006\/bbrc.1993.2659","article-title":"Characterization of a Mutant \u03b1-Galactosidase Gene Product for the Late-Onset Cardiac Form of Fabry Disease","volume":"197","author":"Ishii","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1\u2013galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"ref_107","first-page":"4179","article-title":"In vitro inhibition and intracellular enhancement of lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"JBIC J. Biol. Inorg. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-016-0607-y","article-title":"Migalastat: First Global Approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme re-placement therapy in pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10545-013-9641-z","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry dis-ease","volume":"37","author":"Pisani","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human \u03b1-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Warnock, D.G., Bichet, D.G., Holida, M., Goker-Alpan, O., Nicholls, K., Thomas, M., Eyskens, F., Shankar, S., Adera, M., and Sitaraman, S. (2015). Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active \u03b1-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134341"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Citro, V., Pe\u00f1a-Garc\u00eda, J., Den-Haan, H., P\u00e9rez-S\u00e1nchez, H., del Prete, R., Liguori, L., Cimmaruta, C., Lukas, J., Cubellis, M.V., and Andreotti, G. (2016). Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165463"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-016-0413-3","article-title":"Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients","volume":"11","author":"Smid","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_120","first-page":"1","article-title":"Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: Safety, tolerability, and pharmacokinetics in healthy subjects","volume":"12","author":"Morand","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","article-title":"AAV2\/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction","volume":"18","author":"Yasuda","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ymgme.2018.12.187","article-title":"Liver-targeted AAV gene therapy vectors produced by a clinical scale manu-facturing process result in high, continuous therapeutic levels of enzyme activity and effective sub-strate reduction in mouse model of Fabry disease","volume":"126","author":"Huston","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2018-99-116632","article-title":"Efficacy Evaluation of Liver-Directed Gene Therapy in Fabry Mice","volume":"132","author":"Kia","year":"2018","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before di-agnosis and in the absence of other clinical events: Natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"28339","DOI":"10.1074\/jbc.M400451200","article-title":"Intermediate Trapping on a Mutant Retaining \u03b1-Galactosyltransferase Identifies an Unexpected Aspartate Residue","volume":"279","author":"Lairson","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/84168","article-title":"Crystal structure of the retaining galactosyltransferase LgtC from Neisseria men-ingitidis in complex with donor and acceptor sugar analogs","volume":"8","author":"Persson","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1021\/jacs.5b01156","article-title":"Reaction Mechanisms in Carbohydrate-Active Enzymes: Glycoside Hy-drolases and Glycosyltransferases. Insights from ab Initio Quantum Mechanics\/Molecular Mechan-ics Dynamic Simulations","volume":"137","author":"Rovira","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"10897","DOI":"10.1002\/anie.201104623","article-title":"The Molecular Mechanism of Enzymatic Glycosyl Transfer with Retention of Configuration: Evidence for a Short-Lived Oxocarbenium-Like Species","volume":"50","author":"Rovira","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(15)60206-9","article-title":"Eliglustat for Gaucher\u2019s disease: Trippingly on the tongue","volume":"385","author":"Hughes","year":"2015","journal-title":"Lancet"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Lukas, J., Giese, A.-K., Markoff, A., Grittner, U., Kolodny, E., Mascher, H., Lackner, K.J., Meyer, W., Wree, P., and Saviouk, V. (2013). Functional Characterisation of Alpha-Galactosidase A Mutations as a Basis for a New Classification System in Fabry Disease. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003632"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1002\/anie.200902620","article-title":"Glycosphingolipids-Nature, Function, and Pharmacological Modulation","volume":"48","author":"Wennekes","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"16723","DOI":"10.1074\/jbc.M000728200","article-title":"Cloning and Expression of the Histo-blood Group Pk UDP-galactose:Galbeta 1-4Glcbeta 1-Cer alpha 1,4-Galactosyltransferase","volume":"275","author":"Steffensen","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"15152","DOI":"10.1074\/jbc.M909620199","article-title":"Molecular Cloning of Globotriaosylceramide\/CD77 Synthase, a Glycosyltransferase That Initiates the Synthesis of Globo Series Glycosphingolipids","volume":"275","author":"Kojima","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2016.01.017","article-title":"Human Gb3\/CD77 synthase reveals specificity toward two or four different acceptors depending on amino acid at position 211, creating Pk, P1 and NOR blood group antigens","volume":"470","author":"Kaczmarek","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s10719-016-9716-9","article-title":"Evaluation of an amino acid residue critical for the specificity and activity of human Gb3\/CD77 synthase","volume":"33","author":"Kaczmarek","year":"2016","journal-title":"Glycoconj. J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1537-2995.2007.01552.x","article-title":"Expression of a novel missense mutation found in the A4GALT gene of Amish individuals with the p phenotype","volume":"48","author":"Hellberg","year":"2008","journal-title":"Transfusion"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1365-3148.2010.01055.x","article-title":"Functional characterisation of a complex mutation in the \u03b1(1,4)galactosyltransferase gene in Taiwanese individuals with p phenotype","volume":"21","author":"Wang","year":"2010","journal-title":"Transfus. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1128\/jcm.35.3.609-613.1997","article-title":"Comparison of the Western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring anti-body to Verocytotoxin 1","volume":"35","author":"Reymond","year":"1997","journal-title":"J. Clin. Microbiol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1203\/00006450-200108000-00002","article-title":"Pathogenesis of Shiga Toxin-Associated Hemolytic Uremic Syndrome","volume":"50","author":"Proulx","year":"2001","journal-title":"Pediatr. Res."},{"key":"ref_141","first-page":"99","article-title":"Endocytosis, intracellular transport, and cytotoxic action of Shiga tox-in and ricin","volume":"346","author":"Sandvig","year":"1996","journal-title":"Physiol. Rev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1086\/507705","article-title":"Fabry Disease in Mice Protects against Lethal Disease Caused by Shiga Toxin\u2013Expressing EnterohemorrhagicEscherichia coli","volume":"194","author":"Cilmi","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Tian, S., Muneeruddin, K., Choi, M.Y., Tao, L., Bhuiyan, R.H., Ohmi, Y., Furukawa, K., Furukawa, K., Boland, S., and Shaffer, S.A. (2018). Genome-wide CRISPR screens for Shiga toxins and ricin reveal Golgi proteins critical for glycosylation. PLoS Biol., 16.","DOI":"10.1371\/journal.pbio.2006951"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.isci.2018.12.039","article-title":"A CRISPR Screen Identifies LAPTM4A and TM9SF Proteins as Glycolipid-Regulating Factors","volume":"11","author":"Yamaji","year":"2019","journal-title":"iScience"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nchembio.1029","article-title":"Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology","volume":"8","author":"Gloster","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"21413","DOI":"10.1074\/jbc.M110.207670","article-title":"Adamantyl Glycosphingolipids Provide a New Approach to the Selective Regulation of Cellular Glycosphingolipid Metabolism","volume":"286","author":"Kamani","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1021\/ja101231a","article-title":"UDP-(5F)-GlcNAc acts as a slow-binding inhibitor of MshA, a retaining glycosyltransferase","volume":"132","author":"Frantom","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"11630","DOI":"10.1021\/bi700863s","article-title":"Glycosyltransferase Mechanisms: Impact of a 5-Fluoro Substituent in Acceptor and Donor Substrates on Catalysis","volume":"46","author":"Hartman","year":"2007","journal-title":"Biochemistry"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jmb.2007.04.012","article-title":"Conformational Changes Induced by Binding UDP-2F-galactose to \u03b1-1,3 Galactosyltransferase- Implications for Catalysis","volume":"369","author":"Jamaluddin","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1039\/b821058f","article-title":"Chemoenzymatic syntheses of carbasugar analogues of nucleoside diphosphate sugars: UDP-carba-Gal, UDP-carba-GlcNAc, UDP-carba-Glc, and GDP-carba-Man","volume":"1733\u20131735","author":"Seo","year":"2009","journal-title":"Chem. Commun."},{"key":"ref_151","first-page":"3167","article-title":"Synthesis and evaluation of transition-state ana-logue inhibitors of \u03b1-1,3-fucosyltransferase. Angew","volume":"114","author":"Mitchell","year":"2002","journal-title":"Chem. Int. Ed."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1021\/jm201154p","article-title":"Inhibition of Galactosyltransferases by a Novel Class of Donor Analogues","volume":"55","author":"Descroix","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0960-894X(00)80055-4","article-title":"A new galactosyl transferase inhibitor","volume":"3","author":"Schmidt","year":"1993","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.carres.2014.12.005","article-title":"A Enzymatic synthesis of nucleobase-modified UDP-sugars: Scope and limita-tions","volume":"404","author":"Wagstaff","year":"2015","journal-title":"Carbohydr. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nchembio.343","article-title":"Structural and mechanistic basis for a new mode of glycosyltransferase inhibition","volume":"6","author":"Pesnot","year":"2010","journal-title":"Nat. Chem. Biol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/2\/271\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:23:20Z","timestamp":1760160200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/2\/271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":155,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["biom11020271"],"URL":"https:\/\/doi.org\/10.3390\/biom11020271","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]}}}